Observational studyRMD open2026
Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry.
Observational study in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify factors associated with the effectiveness and safety of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), as reflected by treatment retention.
methodsThis retrospective cohort study used data from the JAGUAR Registry, a multicentre RA registry of JAK inhibitor treatments. At 1 and 4 years, reasons and rates of treatment discontinuation were assessed. Treatment retention was evaluated using Cox regression and Kaplan-Meier curves. Factors associated with treatment retention were analysed for the discontinuation reasons of lack of effectiveness and adverse drug reactions (ADRs).
resultsA total of 435 treatment episodes with JAK inhibitors (tofacitinib: 118, baricitinib: 181, upadacitinib: 80, filgotinib: 56) were included. At 1 year, discontinuation rates were: 23.0% due to lack of effectiveness, 17.0% due to ADRs and 2.3% due to other reasons. At 4 years, the corresponding discontinuation rates were: 32.9%, 19.5% and 5.5%, respectively. Chronic concomitant glucocorticoid (GC) treatment was associated with JAK inhibitor discontinuation due to lack of effectiveness (p=0.007). Discontinuation rates due to lack of effectiveness were higher in patients requiring GCs for >6 months versus ≤6 months (29.1% vs 18.8% at 1 year; 50.5% vs 32.5% at 4 years). Age was associated with JAK inhibitor discontinuation due to ADRs (p=0.003). Discontinuation rates due to ADRs were higher in patients aged ≥65 years versus <65 years (25.6% vs 14.5% at 1 year; 35.3% vs 17.4% at 4 years).
conclusionsIn RA, chronic concomitant GC treatment and patient age are associated with JAK inhibitor discontinuation due to lack of effectiveness and ADRs, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.